scholarly journals Drug–Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV

Drug Safety ◽  
2016 ◽  
Vol 39 (11) ◽  
pp. 1053-1072 ◽  
Author(s):  
Kimberly K. Scarsi ◽  
Kristin M. Darin ◽  
Catherine A. Chappell ◽  
Stephanie M. Nitz ◽  
Mohammed Lamorde
2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S662-S662
Author(s):  
Milena M McLaughlin ◽  
Ashley Jensen ◽  
Susan Cohn ◽  
Kristin Darin

2022 ◽  
Vol 19 (1) ◽  
Author(s):  
Chadni C. Khondoker ◽  
Angela Kaida ◽  
Anna Marquez ◽  
Amber R. Campbell ◽  
Hélène C. F. Côté ◽  
...  

Abstract Background Multiple contraindications to combined hormonal contraceptives (CHC) use exist. The impact of these factors on contraceptive choice, particularly among women living with HIV (WLWH), is not well understood. We measured and compared the prevalence of contraceptive use and contraindications among WLWH and women not living with HIV (controls). Methods We examined cross-sectional survey and medical chart data from 83 WLWH and 62 controls, aged 16–49 and sexually active, from 2013–2017. We compared the age-adjusted prevalence and types of contraceptives used in the last month and the proportion of women with CHC contraindications, including drug interactions, medical comorbidities, and smoking at ≥ 35 years old. All WLWH received care at an interdisciplinary, women-centred HIV clinic. Results Compared to controls, WLWH were older (median [IQR)] 39 [34–43] vs 31 [23–41] years; p = 0.003), had less post-secondary education (37% vs 73%; p < 0.001), and more often had household income < $15,000/year (49% vs 30%; p = 0.006). WLWH trended to higher contraceptive prevalence than controls (80% vs 63%; p = 0.06 adjusted for age). Overall hormonal contraceptive use was similar. However, despite controlling for age, WLWH used CHC less (4% vs 18%; p = 0.006) than controls, and had more frequently undergone tubal ligation (12% vs 2%; p = 0.03). WLWH also experienced more CHC contraindications (54% vs 13%; p = 0.0001), including smoking at ≥ 35 years old (30% vs 6%; p = 0.0003) or a CHC-related drug interaction (all antiretroviral related) (25% vs 0%; p = 0.0001). Conclusions WLWH attending our interdisciplinary clinic used hormonal contraception at similar rates as controls, though with different types. Differences may reflect different distributions of CHC contraindications. CHC contraindications present barriers to accessing the full range of contraceptive choices for WLWH. Guidelines and education for care providers and WLWH regarding contraceptive choices and drug interactions are needed, especially when care is provided without the benefit of an interdisciplinary women-centered healthcare team.


2020 ◽  
Vol 59 (10) ◽  
pp. 1217-1236
Author(s):  
Vera E. Bukkems ◽  
Angela Colbers ◽  
Catia Marzolini ◽  
Jose Molto ◽  
David M. Burger

Contraception ◽  
2016 ◽  
Vol 93 (1) ◽  
pp. 11-16 ◽  
Author(s):  
Sharon J. Phillips ◽  
Chelsea B. Polis ◽  
Kathryn M. Curtis

2012 ◽  
Author(s):  
Hind Khatib-Othman ◽  
Shereen el-Feki ◽  
Kamal Mountasser ◽  
Hend Sabry ◽  
Rita Wahab

Sign in / Sign up

Export Citation Format

Share Document